Navigation Links
International malaria research consortium tackles deadly disease
Date:10/26/2010

Toronto, Canada and New Delhi, India, October 27, 2010 -- Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

Malaria is one of humanities most devastating illnesses with an estimated 247 million cases worldwide in 2008 and almost one million deaths- mostly among children. In Africa a child dies every 45 seconds of Malaria and the disease accounts for 20% of all childhood deaths. Furthermore drug resistance is steadily undermining the effectiveness of existing treatments - driving the need for new therapies.

Each of the consortium's five partners brings unique capabilities spanning the spectrum from academic research to commercial development. They also bring their existing technologies to the table and have hit upon unique combinations of these existing technologies which, when combined with new drugs, represent entirely new approaches to treating and potentially eradicating this disease.

'It was a fascinating process to see different organizations with deep knowledge in their individual fields coming together and combining this knowledge to create innovative and new approaches to the treatment of this disease'' Prof. Virander Chauhan, Director, International Center for Genetic Engineering and Biotechnology-New Delhi

""Creative leverage" is a term that comes to mind in describing this program - in addition to developing new therapeutics, we are also bringing together existing technologies developed by the partners and combining them in new ways such that one will have the potential to boost the effectiveness of another." Dr. Lakshmi P. Kotra, Director, Center for Molecular Design and Preformulations, University Health Network and University of Toronto.

In a field that has seen very few new drugs introduced in the past 30 years, and where most of these drugs have lost effectiveness due to the emergence of drug resistant malaria strains, this program endeavors to develop entirely new classes of drugs, and furthermore will seek to develop drugs that, by their design, will hinder the emergence of drug resistance.

With funding from International Science and Technology Partnerships Canada Inc. (ISTP Canada) and the Department of Biotechnology (DBT) of the Government of India, these new therapies will be developed and refined. Led by the site directors of each partner, Lakshmi Kotra at University Health Network/University of Toronto (Consortium lead in Canada), David Bell at Therapure Biopharma, Jitendra Verma at Lifecare Innovations, Asif Mohammed at the International Center for Genetic Engineering and Biotechnology (Consortium lead in India), and R. Mahesh at Birla Institute of Technology and Science, this program brings together a dynamic and talented groups of world-class scientists for a common cause of advancing basic research discoveries to preclinical development.

Current projects include the development of drugs against three malaria targets that the academic groups have researched extensively. This research is combined with the state-of-the-art tools and expertise in computer modeling, medicinal chemistry and drug delivery to advance potential drugs to the point where human studies can begin. The consortium is making excellent progress and is open to additional partners with the same vision.

One example of this technology combination process is embodied in an objective to treat a form of malaria that resides in the liver. This form of the disease can re-emerge months or years after the initial infection to cause new illnesses in that individual. Additionally this form of the disease can re-introduce malaria into local populations where it had previously been eliminated - frustrating permanent eradication efforts. To tackle this problem the program will combine new drugs developed with a novel technology from one of the consortium partners that is designed to deliver drugs to the liver in an effective form.

Other technology harnessed under the program will allow antimalarial drugs to be released slowly over long periods of time. This slow release gives the potential for a "one pill cure" an accomplishment which would revolutionize the treatment of malaria in a cost-effective manner.


'/>"/>

Contact: Dr. Lakshmi P. Kotra
lkotra@uhnres.utoronto.ca
416-581-7601
University Health Network
Source:Eurekalert

Related biology news :

1. International Rectal Microbicide Advocates cheers launch of worlds third rectal microbicide trial
2. UCLA receives $12.5M to lead international project to study proteins implicated in heart disease
3. Pharmaceutical sciences experts present cutting-edge research at international meeting
4. John P. Holdren addresses climate change, stressing need for international cooperation
5. International scientific forum on alcohol research
6. Stem Cells and International Stem Cell Symposium present annual stem cells award
7. Professor Rajeshwar Dayal Tyagi of INRS wins major international award
8. SailPoint Signs International Reseller Agreement with BMC Software
9. University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life
10. $22.5 million grant funds international study of membrane proteins
11. SRI International President and CEO Curtis R. Carlson Named to National Advisory Council on Innovation and Entrepreneurship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
Breaking Biology News(10 mins):
(Date:9/22/2017)... ... September 22, 2017 , ... The ... Denver, Colorado October 28 and 29, 2017, to promote AMA’s programs, member services, ... participation in different hobbies, including but not limited to model aviation and other ...
(Date:9/21/2017)... ... ... Greg Leyer, Chief Scientific Officer of UAS Labs, will be presenting at SupplySide West ... Probiotics Resource Center, Mandalay Bay Expo Hall. , “I am very pleased to ... data in areas outside the gut including heart health, Vitamin D status, upper respiratory ...
(Date:9/21/2017)... ... September 21, 2017 , ... Executives and subject ... most progressive pharma and biotech organizations to do more clinical trials will share ... events in Q4. , DrugDev will demonstrate DrugDev Spark™, the world’s first unified ...
(Date:9/21/2017)... DIEGO, CALIF. (PRWEB) , ... September 21, 2017 , ... ... earlier this month. The organization, a worldwide society of professional women with high ... venue to hold its annual dinner. , Twelve members began with an ...
Breaking Biology Technology: